Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24804266 | 1.00 | ALDH1A1 (0.52) | ALDH1A1EPHX2SCN9AHTTIDO1 | |
| SCHEMBL23978768 | 1.00 | ALDH1A1 (0.52) | ALDH1A1EPHX2SCN9AHTTIDO1 | |
| SCHEMBL30279443 | 1.00 | ALDH1A1 (0.52) | ALDH1A1EPHX2SCN9AHTTIDO1 | |
| SCHEMBL24106073 | 0.91 | USP2 (0.54) | ALDH1A1EPHX2SCN9AHTTUSP2 | |
| SCHEMBL30083843 | 0.89 | EPHX2 (0.50) | ALDH1A1EPHX2SCN9AHTTUSP2 | |
| SCHEMBL24804772 | 0.89 | EPHX2 (0.50) | ALDH1A1EPHX2SCN9AHTTUSP2 | |
| SCHEMBL24805458 | 0.89 | EPHX2 (0.50) | ALDH1A1EPHX2SCN9AHTTUSP2 | |
| SCHEMBL29019147 | 0.87 | TRPV1 (0.45) | ALDH1A1SCN9A | |
| SCHEMBL29019148 | 0.84 | EPHX2 (0.55) | ALDH1A1EPHX2HTTIDO1USP2 | |
| SCHEMBL26505060 | 0.84 | EPHX2 (0.46) | ALDH1A1EPHX2SCN9AHTTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | ALDH1A1 399/4885EPHX2 1037/4885SCN9A 440/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | ALDH1A1 399/4885EPHX2 1037/4885SCN9A 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.